27
https://pubmed.ncbi.nlm.nih.gov/38114991
The combination of pyrotinib, trastuzumab, and chemotherapy as neoadjuvant therapy for HER2-positive breast cancer results in higher pathological complete response rates compared to trastuzumab and chemotherapy alone, with manageable side effects.